Evolving Strategies for the Management of Hereditary Angioedema – A Patient-Centered Approach With Real-World Examples

Hereditary angioedema (HAE) is a rare autosomal-dominant disorder that affects approximately 1 in 50,000 people worldwide. Individuals with HAE typically experience recurrent painful swelling of the extremities, face, or genitals, in addition to gastrointestinal attacks and potentially fatal laryngeal edema. Furthermore, these swelling episodes are often associated with disfigurement, significant functional impairment, and decreased quality of life (QOL). Despite the existence of specific diagnostic criteria, diagnosis may be delayed by up to 15 years, leading to delays in optimal treatment with available on-demand and prophylactic therapies. Additionally, several novel agents are in development. Given the range of treatment options (eg, formulations, administration routes, dosing strategies), timely diagnosis and personalized treatment plans and a shared decision-making approach are essential to ensure appropriate utilization of prescribed treatment and quick recovery from attacks.

Join our expert faculty in this case-based activity to explore a tailored approach that not only enhances treatment adherence and efficacy but also significantly improves patient QOL, ensuring that clinicians can better address the complexities of HAE to promote improved health outcomes and reduced morbidity.

TARGET AUDIENCE

This educational activity has been designed to meet the needs of allergists, immunologists, nurse practitioners, physician assistants, and other healthcare providers who manage patients with HAE.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Apply guideline-recommended strategies to accurately identify patients with HAE
• Analyze and compare approved and emerging treatment options for managing HAE effectively
• Utilize shared decision-making and validated assessment tools in the development of treatment plans for patients with HAE